Clinical Trials
Clinical trials are central to the research being conducted by the Mayo Nephrology Collaborative Group. Clinical trials offer new options for patients from around the world seeking access to experimental procedures and drugs in all phases of development.
These studies are currently open for enrollment:
Daratumumab to Treat Active Lupus Nephritis
The purpose of this study is to assess the effectiveness and safety of daratumumab in inducing complete or partial remission in patients with active class III or IV (± V) lupus nephritis (LN) as measured by change in proteinuria and serum creatinine.
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits (PGNMID)
The purpose of this study is to assess the effectiveness and safety of daratumumab in inducing complete or partial remission in patients with active class III or IV (± V) lupus nephritis (LN) as measured by change in proteinuria and serum creatinine.
The purpose of this study is to:
- Assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 months.
- Assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications and cytopenias.
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
The purpose of this study is to determine if obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis.
Biospecimens Resource for Glomerular and Tubulo-interstitial Diseases
This study is being done to create a resource of samples that can be used to improve the ability to diagnose and treat MN, IgAN, MPGN, FSGS/MCD, lupus nephritis, AAV and other glomerular tubulo-interstitial disease.